OncoMatch/Clinical Trials/NCT06734182
Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer
Is NCT06734182 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Envafolimab injections+intravenous Disitamab Vedotin+carboplatin for non-small cell lung cancer.
Treatment: Envafolimab injections+intravenous Disitamab Vedotin+carboplatin — This is a prospective, single-arm, multi-center, phase II clinical study to evaluate the efficacy and safety of Envafolimab injection (PD-L1) combined with Disitamab Vedotin (HER2 ADC) and Carboplatin for resectable, HER2-Mutant, stage II-IIIB, NSCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) mutation
HER2 mutations identified by histological specimens
Required: EGFR sensitizing mutation
Participants with known EGFR sensitive mutations
Required: ALK fusion
Participants with known...ALK translocation
Required: KRAS sensitizing mutation
KRAS sensitive mutations
Required: BRAF V600E
BRAF V600E
Required: ROS1 fusion
ROS1 fusions
Required: RET fusion
RET fusions
Required: MET exon 14 alteration
MET exon 14 alterations
Required: MET amplification
MET amplification
Required: NTRK1 fusion
NTRK fusions
Required: NTRK2 fusion
NTRK fusions
Required: NTRK3 fusion
NTRK fusions
Disease stage
Required: Stage II, IIIA, IIIB (AJCC version 9)
Excluded: Stage IIIC
resectable, stage II, IIIA, IIIB (AJCC staging system, version 9) NSCLC; unresectable includes the unresectable defined in the Chinese expert consensus on the multidisciplinary diagnosis and treatment for stage III non-small cell lung cancer (2019), including partial stage IIIA and IIIB and all the stage IIIC
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic antitumor therapy
Previous treatment with systemic antitumor therapy for early NSCLC, including investigational product
Cannot have received: PD-1/PD-L1 agent or drug acting on another targeted T cell receptor
Previous use of PD-1/PD-L1 agent or the drug acting on another targeted T cell receptor (e.g., CTLA-4, OX-40)
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06734182 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 mutation is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR sensitizing mutation is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK fusion is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or IIIA or IIIB is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify